High risk of recurrence of two life-threatening adverse drug reactions

Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a study in the June 4 issue of JAMA.

Stevens-Johnson syndrome (SJS) and (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background information in the article.

Yaron Finkelstein, M.D., of the Hospital for Sick Children, Toronto, and colleagues conducted a study that included data of all Ontario residents hospitalized for a first episode of SJS or TEN between April 2002 and March 2011. Patients were followed up from admission until March 31, 2012, or death. The researchers identified 708 individuals hospitalized for a first episode of SJS (n = 567) or TEN (n = 141), including 127 (17.9 percent) children younger than 18 years.

Forty-two patients (7.2 percent) were hospitalized for a subsequent episode of SJS or TEN. Eight patients (1.4 percent) experienced multiple recurrences. The median time to first recurrence was 315 days.

"In light of the reported incidence of SJS and TEN in the general population (1.0-7.2 cases/1 million individuals/year), the observed in our study (>7 percent) is several thousand-fold higher than would be expected if subsequent episodes were probabilistically independent of the first SJS or TEN episode. We speculate that this increased risk reflects individual susceptibility. Genetic predisposition has been identified for several medications in association with specific genotypes …" the authors write.

"… these findings are relevant to physicians who care for with a history of SJS or TEN. Because most such episodes are drug-induced, the of recurrence should be recognized, and the benefits of drug therapy weighed carefully against the potential risks. This is particularly true for drugs commonly associated with the development of these frequently fatal conditions."

More information: DOI: 10.1001/jama.2014.839

add to favorites email to friend print save as pdf

Related Stories

Fetal membrane transplantation prevents blindness

Apr 26, 2012

Transplanting tissue from newborn fetal membranes prevents blindness in patients with a devastating disease called Stevens-Johnson syndrome, a Loyola University Medical Center study has found.

Recommended for you

Spain: Ebola test drug out of supply worldwide

1 hour ago

Doctors treating a Spanish priest who was repatriated from West Africa on Monday after being diagnosed with the Ebola virus said there were no samples of experimental drug ZMapp available in the world right ...

A multiscale approach to Ebola response

2 hours ago

The Ebola outbreak in western Africa continues to spread uncontrolled, affecting thus far five countries. On September 16th, President Obama spoke at the Centers for Disease Control and Prevention headquarters ...

Overwhelmed west Africa ramps up Ebola response

17 hours ago

West Africa intensified its response to the deadly Ebola epidemic on Sunday, with Sierra Leone uncovering scores of dead bodies during a 72-hour shutdown and Liberia announcing hundreds of new hospital beds.

Sierra Leone reaches final day of Ebola lockdown

20 hours ago

Frustrated residents complained of food shortages in some neighborhoods of Sierra Leone's capital on Sunday as the country reached the third and final day of a sweeping, unprecedented lockdown designed to ...

User comments